Table 2.
The distribution of LPA CNVs in cases and controls and the risk prediction of CAD
| LPA CNVs | CAD, n (%) | NCA, n (%) | PΧ2 a | Crude | Adjustedb | ||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||
| OR | 95% CI | P | OR | 95% CI | P | ||||
| 1 | 85 (31.4) | 90 (43.5) | 0.002 | 0.64 | 0.44-0.93 | 0.02 | 0.38 | 0.23-0.64 | 0.00 |
| 2 | 169 (62.4) | 114 (55.1) | 1.00 (reference) | 1.00 (reference) | |||||
| 3 | 17 (6.3) | 3 (1.4) | 3.82 | 1.10-13.34 | 0.04 | 4.93 | 0.91-26.86 | >0.07 | |
a
P values were calculated by the χ2 test for differences in LPA CNVs between patients and controls.
b
ORs adjusted for age, gender, BMI, diabetes, hypertension, stroke history, smoking habit, Lp(a) and hyperlipidaemia.